 ORWH Hosts 6th Annual Vivian W. Pinn Symposium, May 12
ORWH will host the 6th Annual Vivian W. Pinn Symposium. Held annually during National Women's Health Week, the symposium is ORWH's signature event, honoring the first full-time director of ORWH. The title of this year’s symposium is “The Impact of the COVID-19 Pandemic on the Careers of Women Scientists"…Read More.
ORWH Marks the 5th Anniversary of the U3 Administrative Supplement Program with a new Webpage for Important Milestone
This year is the 5th anniversary of one of ORWH’s signature research programs, the U3 Administrative Supplement Program, which supports research focused on women of populations often understudied, underrepresented, and underreported in clinical research. ORWH marks this important milestone with the launch of the U3 Interdisciplinary Research webpage…Read More.
 Cross-Sectional Analyses of High-Impact Pain Across Pregnancy Status by Race and Ethnicity, Journal of Women's Health, February 2022
Community voices: NIH working toward inclusive excellence by promoting and supporting women in science, Nature Communications, March 2022
Sex as a Biological Variable in Cardiovascular Diseases: JACC Focus Seminar 1/7, Journal of the American College of Cardiology, April 2022
 Request for Information (RFI) inviting comments to inform the NIH on the intersection of the SARS-CoV-2/COVID-19 pandemic and the health of women (NOT-OD-22-092)
Due May 6, 2022
NIH RFI on Interdisciplinary Research Opportunities that Bridge Neuroscience and Environmental Health Science (NOT-NS-22-076)
Due May 7, 2022
Notice of Special Interest (NOSI): Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities (NOT-HD-22-002)
Due June 5, 2022
NOSI: Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioral Health Preventive Interventions in School Settings (NOT-AT-22-004)
Due June 5, 2022
Alcohol Health Services Research (R01 Clinical Trial Optional) (PAR-22-156)
Due June 5, 2022
|
